



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

14 July 2022  
EMA/643852/2022  
European Medicines Agency

## Highlights from the 7<sup>th</sup> meeting of the Nitrosamine Implementation Oversight Group (NIOG)

- The NIOG discussed the approach on the risk of presence of nitrosamine in marketed medicines and also in new applications and line extensions.
- The NIOG noted the approaching call for review deadline for human medicines with chemical active substances (26<sup>th</sup> September 2022) and discussed approaches to facilitate companies to implement adequate remediation actions for products where presence of nitrosamine has been identified while ensuring adequate levels of patient protection and availability of critical medicines.
- The good progress on the engagement and collaboration with international authorities was also recognised.

---

**Official address** Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

**Address for visits and deliveries** Refer to [www.ema.europa.eu/how-to-find-us](http://www.ema.europa.eu/how-to-find-us)

**Send us a question** Go to [www.ema.europa.eu/contact](http://www.ema.europa.eu/contact) **Telephone** +31 (0)88 781 6000

An agency of the European Union



